Dr. John Cush RheumNow
6 years ago
Nonradiographic axial spondyloarthritis= meeting axSpA criteria without Xray sacroiliitis. Swiss study compared women & men w nr-axSpA. Women had a longer Dx delay, higher Dz activity & enthesitis, less B27+ & signif lower TNFi resp rate (OR 0.19) vs Men https://t.co/ykAHfimOd5
A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.
Dr. John Cush RheumNow
6 years ago
The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus? Watch it here> https://t.co/ced3cKg5eB or listent to podcast on iTunes> https://t.co/FHJv01AAbC or SoundCloud> https://t.co/e4nWr3wECz
Dr. John Cush RheumNow
6 years ago
Congratulatons to Professor Ian McInnes on his appointment as Vice Principal & Head of College to the College of Medical, Veterinary and Life Sciences (MVLS), within the University of Glasgow. https://t.co/m3joegAEsK
Dr. John Cush RheumNow
6 years ago
Congratulations to #NIH's Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), on winning the 2020 Federal Employee of the Year award! #Sammies2020 https://t.co/S5n3M97o8d
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
A total of 4716 patients who were hospitalized with Covid-19 were randomly to receive HCQ (1561 patients) or usual care (3155). The primary endpoint was 28-day mortality.
Dr. John Cush RheumNow
6 years ago
Another case of COVID-19 Arthritis; 58 yoF w/ non-severe COVID-19, (by qRT-PCR ) had arthralgia, fever, cough, nausea, diarrhoea, dysgeusia, and devloped ankle arthritis CRP 7·36 mg/L, lymphopenia (1·29) persistent arthritis (by US) and +Sars-CoV-2 in SF. https://t.co/4Pg1Vq30EN
Victoria Shanmugam VickiShanmugam
6 years ago
#WomenInMedicine now that we have data from @NEJM - how do we help institutions work with women to address these challenges together? https://t.co/kEyegOCfE3
Mike Putman EBRheum
6 years ago
Excellent review of IgG4-RD, @NatRevRheumatol
IgG4-RD is indolent (afebrile, etc) but 60% of pts have irreversible damage at dx!
Universal response to GC but 40% not in remission at 1yr; B-cell tx can bring about "dramatic response"
Good read & topic: https://t.co/Mbrq7bFHk0 https://t.co/8oQF08qzit
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
QD Clinic - No Show Nancy
Considerations on no-show patients
Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.
Among 63 patients who were treated with rituximab (Rituxan), remission or partial responses at 1 year were observed in 49% and 24% of patients, respectively, reported Benjamin Terrier, MD, PhD, of Université Paris Descartes in Paris, and colleagues.
A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.
